采用利妥昔单抗和地塞米松诱导治疗，随后使用利妥昔单抗维持治疗，成功治愈IgG4相关性肥厚性硬脑膜炎。
Successful treatment of IgG4-related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab.
作者信息
Seegobin Karan, Moustafa Muhamad A, Gannon Nicole, Keller Katelyn, Hastings Jacquelyn, Gupta Vivek, Tun Han W, Jiang Liuyan
机构信息
Division of Haematology and Medical Oncology Mayo Clinic Jacksonville Florida Jacksonville FL USA.
Department of Radiology Mayo Clinic Jacksonville Florida Jacksonville FL USA.
出版信息
Clin Case Rep. 2021 Jan 27;9(3):1610-1614. doi: 10.1002/ccr3.3855. eCollection 2021 Mar.
Abstract
IgG4-related disease (IgG4RD) with intracranial involvement is rare. We report a 56-year-old male who had an excellent response to rituximab and dexamethasone after going undiagnosed for 5 years. After 3 years of rituximab maintenance, he has no evidence of disease on brain MRI.
摘要
IgG4相关性疾病（IgG4RD）累及颅内者较为罕见。我们报告一名56岁男性，在未被诊断5年后，接受利妥昔单抗和地塞米松治疗后反应良好。在接受利妥昔单抗维持治疗3年后，其脑部MRI检查未发现疾病迹象。
相似文献
1
Successful treatment of IgG4-related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab.
Clin Case Rep. 2021 Jan 27;9(3):1610-1614. doi: 10.1002/ccr3.3855. eCollection 2021 Mar.
2
Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report.
Front Neurol. 2023 May 24;14:1189778. doi: 10.3389/fneur.2023.1189778. eCollection 2023.
3
Intrathecal IgG4 synthesis in IgG4 related spinal hypertrophic pachymeningitis: a case report.
Neurol Res Pract. 2024 Aug 29;6(1):43. doi: 10.1186/s42466-024-00343-2.
4
Pachymeningitis associated with IgG4-related disease and ANCA positivity: Case report and review of the literature.
Autoimmun Rev. 2023 Apr;22(4):103285. doi: 10.1016/j.autrev.2023.103285. Epub 2023 Feb 2.
5
Polycystic subdural hygroma associated with immunoglobulin G4-related intracranial hypertrophic pachymeningitis: a case report.
BMC Neurol. 2020 Jun 4;20(1):228. doi: 10.1186/s12883-020-01815-z.
6
A Case of Hypertrophic Pachymeningitis Associated with Immunoglobulin-G4 and c-ANCA.
Case Rep Neurol. 2019 Oct 28;11(3):290-294. doi: 10.1159/000502569. eCollection 2019 Sep-Dec.
7
Immunoglobulin-G4-related hypertrophic pachymeningitis with antineutrophil cytoplasmatic antibodies effectively treated with rituximab.
J Clin Neurosci. 2015 Jun;22(6):1038-40. doi: 10.1016/j.jocn.2014.12.020. Epub 2015 Apr 7.
8
[Pachymeningitis associated with IgG4 disease].
Medicina (B Aires). 2017;77(3):242-244.
9
Intrathecal rituximab in immunoglobulin G4-hypertrophic pachymeningitis.
J Neuroimmunol. 2019 Sep 15;334:576997. doi: 10.1016/j.jneuroim.2019.576997. Epub 2019 Jun 19.
10
Hypertrophic pachymeningitis due to IgG4-related disease (RD-IgG4). A case report.
Reumatol Clin (Engl Ed). 2023 Jun-Jul;19(6):338-344. doi: 10.1016/j.reumae.2023.05.001. Epub 2023 May 11.
引用本文的文献
1
Immunoglobulin G4 biomarkers and pathogenesis in immunoglobulin G4-related spinal pachymeningitis.
World J Clin Cases. 2025 Aug 6;13(22):105331. doi: 10.12998/wjcc.v13.i22.105331.
2
Clinical features of immunoglobulin G4-related spinal pachymeningitis.
Front Hum Neurosci. 2025 Jul 17;19:1541096. doi: 10.3389/fnhum.2025.1541096. eCollection 2025.
3
Complete remission of central nervous system manifestations of IgG4-related disease with rituximab - a case report.
Ther Adv Neurol Disord. 2023 Jul 18;16:17562864231186091. doi: 10.1177/17562864231186091. eCollection 2023.
4
Immune Dysregulation in IgG-Related Disease.
Front Immunol. 2021 Sep 1;12:738540. doi: 10.3389/fimmu.2021.738540. eCollection 2021.
本文引用的文献
1
Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review.
Neurol Neuroimmunol Neuroinflamm. 2019 May 7;6(4):e568. doi: 10.1212/NXI.0000000000000568. eCollection 2019 Jul.
2
IgG4-Related Sclerosing Disease Causing Spinal Cord Compression: The First Reported Case in Literature.
Case Reports Immunol. 2019 Jun 18;2019:3618510. doi: 10.1155/2019/3618510. eCollection 2019.
3
IgG4-related intracranial disease.
Neuroradiol J. 2019 Feb;32(1):29-35. doi: 10.1177/1971400918806323. Epub 2018 Oct 15.
4
Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1947-1953. doi: 10.1016/j.cgh.2018.02.049. Epub 2018 Mar 8.
5
Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases.
Pract Neurol. 2018 Apr;18(2):159-161. doi: 10.1136/practneurol-2017-001826. Epub 2017 Dec 5.
6
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
PLoS One. 2017 Sep 15;12(9):e0183844. doi: 10.1371/journal.pone.0183844. eCollection 2017.
7
Neurological Manifestations of IgG4-Related Disease.
Curr Treat Options Neurol. 2017 Apr;19(4):14. doi: 10.1007/s11940-017-0450-9.
8
Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis.
J Clin Neurol. 2017 Apr;13(2):155-161. doi: 10.3988/jcn.2017.13.2.155. Epub 2017 Mar 6.
9
Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of rituximab.
J Neuroimmunol. 2016 Oct 15;299:62-65. doi: 10.1016/j.jneuroim.2016.08.009. Epub 2016 Aug 16.
10
Refractory IgG4-related intracranial hypertrophic pachymeningitis responded to rituximab.
Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e41. doi: 10.1212/NXI.0000000000000041. eCollection 2014 Dec.
Zotero 插件